14 results found.

Recurrent Melanoma, or Stage IV Melanoma Clinical Trial using NA17.A2 peptide vaccine; recombinant MAGE-3.1 antigen; recombinant interleukin-12; MART-1 antigen; laboratory biomarker analysis

National Cancer Institute (NCI) - Recruiting 18 years or older.
- A Randomized Phase II Study of Multipeptide Vaccination With or Without IL-12, Then Combined With Regulatory T Cell Depletion Using Daclizumab in Patients With Metastatic Melanoma.
NA17.A2 peptide vaccine; recombinant MAGE-3.1 antigen; recombinant interleukin-12; MART-1 antigen; laboratory biomarker analysis

Recurrent Melanoma, Stage IA Melanoma, Stage IB Melanoma, Stage I Clinical Trial using fluorescein sodium injection; diagnostic microscopy; therapeutic conventional surgery; laboratory biomarker analysis

Roswell Park Cancer Institute - Recruiting 18 years or older.
- A Pilot Study of Feasibility of Performing Intravital Microscopy in Melanoma Patients.
fluorescein sodium injection; diagnostic microscopy; therapeutic conventional surgery; laboratory biomarker analysis

Recurrent Melanoma, Stage IV Melanoma, or Tumors Metastatic to Br Clinical Trial using Ipilimumab; Whole-Brain Radiation Therapy (WBRT); Stereotactic Radiosurgery (SRS)

Thomas Jefferson University - Recruiting 18 years or older.
- Phase I Study of Ipilimumab Combined With Whole Brain Radiation Therapy or Radiosurgery for Melanoma Patients With Brain Metastases.
Ipilimumab; Whole-Brain Radiation Therapy (WBRT); Stereotactic Radiosurgery (SRS)

Recurrent Melanoma, Stage IIIA Melanoma, Stage IIIB Melanoma, Sta Clinical Trial using dabrafenib; ipilimumab; trametinib; laboratory biomarker analysis

National Cancer Institute (NCI) - Recruiting 18 years or older.
- A Sequential Safety and Biomarker Study of BRAF-MEK Inhibition on the Immune Response in the Context of CTLA-4 Blockade for BRAF Mutant Melanoma.
dabrafenib; ipilimumab; trametinib; laboratory biomarker analysis

Recurrent Melanoma, Stage IIIA Melanoma, Stage IIIB Melanoma, Sta Clinical Trial using cyclophosphamide; fludarabine phosphate; therapeutic tumor infiltrating lymphocytes; aldesleukin; laboratory biomarker analysis

Fred Hutchinson Cancer Research Center - Recruiting 18 years or older.
- Cellular Adoptive Immunotherapy Using Autologous Tumor-Infiltrating Lymphocytes Following Lymphodepletion With Cyclophosphamide and Fludarabine for Patients With Metastatic Melanoma.
cyclophosphamide; fludarabine phosphate; therapeutic tumor infiltrating lymphocytes; aldesleukin; laboratory biomarker analysis

Recurrent Melanoma, Stage IIIA Melanoma, Stage IIIB Melanoma, Sta Clinical Trial using dabrafenib; trametinib; navitoclax; pharmacological study; laboratory biomarker analysis

National Cancer Institute (NCI) - Recruiting 18 years or older.
- Phase I/II Study of Dabrafenib, Trametinib, and Navitoclax in BRAF Mutant Melanoma and Other Solid Tumors.
dabrafenib; trametinib; navitoclax; pharmacological study; laboratory biomarker analysis

Recurrent Melanoma, Stage IIIB Melanoma, Stage IIIC Melanoma, or Clinical Trial using ipilimumab; recombinant interferon alfa-2b; quality-of-life assessment

National Cancer Institute (NCI) - Recruiting 18 years or older.
- A Phase III Randomized Study of Adjuvant Ipilimumab Anti-CTLA4 Therapy Versus High-Dose Interferon a-2b for Resected High-Risk Melanoma.
ipilimumab; recombinant interferon alfa-2b; quality-of-life assessment

Male Breast Cancer, Recurrent Melanoma, Stage IV Breast Cancer, S Clinical Trial using propranolol hydrochloride; Correlative Studies

Ohio State University Comprehensive Cancer Center - Recruiting 18 years or older.
- A Pilot Study of Beta-Blockers in Patients With Advanced Cancer.
propranolol hydrochloride; Correlative Studies

Recurrent Melanoma, Recurrent Thyroid Cancer, Thyroid Gland Medul Clinical Trial using cabozantinib-s-malate; pharmacological study; laboratory biomarker analysis

National Cancer Institute (NCI) - Recruiting 2 years to 18 years.
- A Phase 1 Study of XL184 (Cabozantinib, IND# 116059) in Children and Adolescents With Recurrent or Refractory Solid Tumors, Including CNS Tumors.
cabozantinib-s-malate; pharmacological study; laboratory biomarker analysis

Recurrent Melanoma, Stage IIIB Melanoma, Stage IIIC Melanoma, or Clinical Trial using recombinant hsp110-gp100 chaperone complex vaccine

Roswell Park Cancer Institute - Recruiting 18 years or older.
- A Phase I Trial of a Recombinant Human hsp110-gp100 Chaperone Complex Vaccine for Advanced Stage IIIB/C or IV Melanoma.
recombinant hsp110-gp100 chaperone complex vaccine

Brain Metastases, Lung Cancer, Breast Cancer, Melanoma, or Malign Clinical Trial using 2B3-101; Trastuzumab; 2B3-101 60 mg/m2 every 4 weeks; 2B3-101 50 mg/m2 every 3 weeks

to-BBB technologies B.V. - Recruiting 18 years or older.
- An Open-label, Phase I/IIa, Dose Escalating Study of 2B3-101 in Patients With Solid Tumors and Brain Metastases or Recurrent Malignant Glioma..
2B3-101; Trastuzumab; 2B3-101 60 mg/m2 every 4 weeks; 2B3-101 50 mg/m2 every 3 weeks

Recurrent Melanoma, Stage IIIA Melanoma, Stage IIIB Melanoma, Sta Clinical Trial using ipilimumab; recombinant interferon alfa-2b; laboratory biomarker analysis

National Cancer Institute (NCI) - Recruiting 18 years or older.
- A Randomized Phase II Study of Ipilimumab at 3 mg/kg or 10 mg/kg Alone or in Combination With High Dose Interferon-Alpha in Advanced Melanoma.
ipilimumab; recombinant interferon alfa-2b; laboratory biomarker analysis

Recurrent Melanoma, Stage IIIA Melanoma, Stage IIIB Melanoma, Sta Clinical Trial using riluzole; sorafenib tosylate; diagnostic laboratory biomarker analysis; pharmacological study

National Cancer Institute (NCI) - Recruiting 18 years or older.
- A Phase I Trial of Riluzole and Sorafenib in Patients With Advanced Solid Tumors and Melanoma.
riluzole; sorafenib tosylate; diagnostic laboratory biomarker analysis; pharmacological study

Advanced Solid Tumors Clinical Trial using E7050 plus E7080; E7080 plus E7050; E7050 plus E7080 or E7080 alone plus E7050 add-on therapy; E7050

Eisai Inc. - Recruiting N/A or older.
- An Open-Label, Multicenter Phase 1b/2 Study of E7050 in Combination With E7080 in Subjects With Advanced Solid Tumors (Dose Escalation) and in Subjects With Recurrent Glioblastoma or Unresectable Stage III or Stage IV Melanoma After Prior Systemic Therapy (Expansion Cohort and Phase 2).
E7050 plus E7080; E7080 plus E7050; E7050 plus E7080 or E7080 alone plus E7050 add-on therapy; E7050